Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kodiak Sciences Inc. (KOD : NSDQ)

• Company Description    Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. It specializes in novel therapeutics to treat chronic and retinal diseases. The company's product candidates consists of KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and Uveitis, KSI-201 for treatment resistant wet AMD and KSI-401 for dry AMD which are in clinical stage. Kodiak Sciences Inc. is based in CA, United States. Number of Employees: 93

• Price / Volume Information    Yesterday's Closing Price: $5.70 Daily Weekly Monthly 20 Day Moving Average: 896,377 shares Shares Outstanding: 51.95 (millions) Market Capitalization: $296.14 (millions) Beta: 1.98 52 Week High: $131.97 52 Week Low: $4.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.90% -3.47% 12 Week -89.16% -88.24% Year To Date -93.28% -92.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 PAGE MILL ROAD - PALO ALTO,CA 94304 USA ph: 650-281-0850 fax: - ir@kodiak.com http://www.kodiak.com

• General Corporate Information    Officers Victor Perlroth - Chief Executive Officer and Chairman John Borgeson - Chief Financial Officer Felix J. Baker - Director Charles Bancroft - Director Bassil I. Dahiyat - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 50015M109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 51.95 Most Recent Split Date: (:1) Beta: 1.98 Market Capitalization: $296.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -86.73% vs. Previous Quarter: -2.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -45.15 12/31/21 - -35.71 09/30/21 - -27.65 ROA 03/31/22 - -33.66 12/31/21 - -27.43 09/30/21 - -21.74 Current Ratio 03/31/22 - 8.94 12/31/21 - 11.36 09/30/21 - 14.81 Quick Ratio 03/31/22 - 8.94 12/31/21 - 11.36 09/30/21 - 14.81 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 11.50 12/31/21 - 12.83 09/30/21 - 14.04 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©